Physician profile
Nathan T Simons
NPI 1568502896
$1,277.37
in general payments reported to CMS, 2019-2025
20 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $100 · 2021: $59.68 · 2022: $171 · 2023: $207 · 2024: $80.86 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $763.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $238.36 | 2020-2025 | Farxiga, Airsupra |
| Pfizer INC. | $215.33 | 2019-2025 | |
| Novo Nordisk INC | $215.27 | 2019-2025 | Ozempic |
| Mylan Specialty L.P. | $70.15 | 2022-2023 | Yupelri |
| Exact Sciences Corporation | $63.06 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $61.54 | 2019-2024 | Mounjaro, Zepbound, Emgality |
| Sanofi-Aventis U.S. LLC | $54.90 | 2019-2021 | |
| Abiomed | $46.36 | 2024-2025 | Impella |
| Acadia Pharmaceuticals INC | $41.29 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $35.23 | 2025 | Gemtesa |
| Cranial Technologies, INC | $33.10 | 2023-2025 | Doc Band |
| Genentech USA, INC. | $30.12 | 2019 | |
| Abbvie INC. | $29.73 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.68 | 2022 | |
| Dexcom, INC. | $26.63 | 2025 | Dexcom G6 Transmitter |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $24.80 | 2025 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $23.01 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.20 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.19 | 2021 | |
| Sunovion Pharmaceuticals INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Simons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.